Literature DB >> 20332244

Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer.

Osama Al-Saif1, William B Farrar, Mark Bloomston, Kyle Porter, Matthew D Ringel, Richard T Kloos.   

Abstract

OBJECTIVE: The objective of the study was to determine the outcome of surgical resection of metastatic papillary thyroid cancer (PTC) in cervical lymph nodes after failure of initial surgery and I(131) therapy.
DESIGN: This was a retrospective clinical study.
SETTING: The study was conducted at a university-based tertiary cancer hospital. PATIENTS: A cohort of 95 consecutive patients with recurrent/persistent PTC in the neck underwent initial reoperation during 1999-2005. All had previous thyroidectomy (+/-nodal dissection) and I(131) therapy. Twenty-five patients with antithyroglobulin (Tg) antibodies were subsequently excluded. MAIN OUTCOME MEASURES: Biochemical complete remission (BCR) was stringently defined as undetectable TSH-stimulated serum Tg.
RESULTS: A total of 107 lymphadenectomies were undertaken in these 70 patients through January 2010. BCR was initially achieved in 12 patients (17%). Of the 58 patients with detectable postoperative Tg, 28 had a second reoperation and BCR was achieved in five (18%), seven had a third reoperation, and none achieved BCR. No patient achieving BCR had a subsequent recurrence after a mean follow-up of 60 months (range 4-116 months). In addition, two more patients achieved BCR during long-term follow-up without further intervention. In total, 19 patients (27%) achieved BCR and 32 patients (46%) achieved a TSH-stimulated Tg less than 2.0 ng/ml. Patients who did not achieve BCR had significant reduction in Tg after the first (P < 0.001) and second (P = 0.008) operations. No patient developed detectable distant metastases or died from PTC.
CONCLUSIONS: Surgical resection of persistent PTC in cervical lymph nodes achieves BCR, when most stringently defined, in 27% of patients, sometimes requiring several surgeries. No biochemical or clinical recurrences occurred during follow-up. In patients who do not achieve BCR, Tg levels were significantly reduced. The long-term durability and impact of this intervention will require further investigation.

Entities:  

Mesh:

Year:  2010        PMID: 20332244      PMCID: PMC5399471          DOI: 10.1210/jc.2010-0063

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

1.  Preoperative neck ultrasonographic mapping for persistent/recurrent papillary thyroid cancer.

Authors:  Hussam M Binyousef; Ali S Alzahrani; Saif S Al-Sobhi; Suhaibani Hamed S Al; Mohammed A Chaudhari; Hussain M Raef
Journal:  World J Surg       Date:  2004-11       Impact factor: 3.352

2.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

Review 3.  Papillary and follicular thyroid carcinoma.

Authors:  M J Schlumberger
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

Review 4.  Well-differentiated thyroid cancer.

Authors:  G H Jossart; O H Clark
Journal:  Curr Probl Surg       Date:  1994-12       Impact factor: 1.909

5.  Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer.

Authors:  John M Stulak; Clive S Grant; David R Farley; Geoffrey B Thompson; Jon A van Heerden; Ian D Hay; Carl C Reading; J William Charboneau
Journal:  Arch Surg       Date:  2006-05

6.  Impact of cervical lymph node dissection on serum TG and the course of disease in TG-positive, radioactive iodine whole body scan-negative recurrent/persistent papillary thyroid cancer.

Authors:  A S Alzahrani; H Raef; A Sultan; S Al Sobhi; S Ingemansson; M Ahmed; A Al Mahfouz
Journal:  J Endocrinol Invest       Date:  2002-06       Impact factor: 4.256

Review 7.  Thyroid cancer nodal metastases: biologic significance and therapeutic considerations.

Authors:  S K Grebe; I D Hay
Journal:  Surg Oncol Clin N Am       Date:  1996-01       Impact factor: 3.495

8.  Efficacy of nodal dissection for treatment of persistent/recurrent papillary thyroid cancer.

Authors:  Kathryn G Schuff; Stephen M Weber; Babak Givi; Mary H Samuels; Peter E Andersen; James I Cohen
Journal:  Laryngoscope       Date:  2008-05       Impact factor: 3.325

9.  Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma.

Authors:  Gary L Clayman; Thomas D Shellenberger; Lawrence E Ginsberg; Beth S Edeiken; Adel K El-Naggar; Rena V Sellin; Steven G Waguespack; Dianna B Roberts; Anupam Mishra; Steven I Sherman
Journal:  Head Neck       Date:  2009-09       Impact factor: 3.147

10.  Phase II trial of sorafenib in metastatic thyroid cancer.

Authors:  Richard T Kloos; Matthew D Ringel; Michael V Knopp; Nathan C Hall; Mark King; Robert Stevens; Jiachao Liang; Paul E Wakely; Vasyl V Vasko; Motoyasu Saji; Jennifer Rittenberry; Lai Wei; Daria Arbogast; Minden Collamore; John J Wright; Michael Grever; Manisha H Shah
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

View more
  31 in total

1.  Longer-term outcomes of radiofrequency ablation for locally recurrent papillary thyroid cancer.

Authors:  Sae Rom Chung; Jung Hwan Baek; Young Jun Choi; Jeong Hyun Lee
Journal:  Eur Radiol       Date:  2019-02-25       Impact factor: 5.315

2.  Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.

Authors:  Aubrey A Carhill; Danielle R Litofsky; Douglas S Ross; Jacqueline Jonklaas; David S Cooper; James D Brierley; Paul W Ladenson; Kenneth B Ain; Henry G Fein; Bryan R Haugen; James Magner; Monica C Skarulis; David L Steward; Mingxhao Xing; Harry R Maxon; Steven I Sherman
Journal:  J Clin Endocrinol Metab       Date:  2015-07-14       Impact factor: 5.958

3.  Application of deep learning to the diagnosis of cervical lymph node metastasis from thyroid cancer with CT.

Authors:  Jeong Hoon Lee; Eun Ju Ha; Ju Han Kim
Journal:  Eur Radiol       Date:  2019-03-15       Impact factor: 5.315

4.  Long-term results of surgery for papillary thyroid carcinoma with local recurrence.

Authors:  Hiroki Uchida; Tsuneo Imai; Toyone Kikumori; Hironori Hayashi; Shigenori Sato; Sumiyo Noda; Ai Idota; Tetsuya Kiuchi
Journal:  Surg Today       Date:  2012-10-10       Impact factor: 2.549

5.  Adjuvant therapy with 131-iodine in patients with elevated serum thyroglobulin after reoperation due to papillary thyroid carcinoma lymph node metastases.

Authors:  Pedro W Rosario; Gabriela F Mourão; Thassio L Siman; Maria R Calsolari
Journal:  Endocrine       Date:  2014-09-10       Impact factor: 3.633

6.  Management and outcome of clinically evident neck recurrence in patients with papillary thyroid cancer.

Authors:  Laura Y Wang; Jocelyn C Migliacci; R Michael Tuttle; Ashok R Shaha; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Clin Endocrinol (Oxf)       Date:  2017-06-14       Impact factor: 3.478

7.  European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 Clinical Practice Guideline for the Use of Minimally Invasive Treatments in Malignant Thyroid Lesions.

Authors:  Giovanni Mauri; Laszlo Hegedüs; Steven Bandula; Roberto Luigi Cazzato; Agnieszka Czarniecka; Oliver Dudeck; Laura Fugazzola; Romana Netea-Maier; Gilles Russ; Göran Wallin; Enrico Papini
Journal:  Eur Thyroid J       Date:  2021-05-25

8.  Evaluating the morbidity and efficacy of reoperative surgery in the central compartment for persistent/recurrent papillary thyroid carcinoma.

Authors:  Brian Hung-Hin Lang; George C C Lee; Cathy P C Ng; Kai Pun Wong; Koon Yat Wan; Chung-Yau Lo
Journal:  World J Surg       Date:  2013-12       Impact factor: 3.352

9.  Recurrent Papillary Thyroid Carcinoma to the Cervical Lymph Nodes: Outcomes of Compartment-Oriented Lymph Node Resection.

Authors:  Carlos Gustavo Rivera-Robledo; David Velázquez-Fernández; Juan Pablo Pantoja; Mauricio Sierra; Bernardo Pérez-Enriquez; Raul Rivera-Moscoso; Mónica Chapa; Miguel F Herrera
Journal:  World J Surg       Date:  2019-11       Impact factor: 3.352

10.  Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer.

Authors:  Matthew L Hung; James X Wu; Ning Li; Masha J Livhits; Michael W Yeh
Journal:  JAMA Surg       Date:  2018-12-01       Impact factor: 14.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.